Siplizumab: all 26 studies that test it
Page 1 of 1. Open to participants first (4), then studies with results posted, then the rest; newest registration first within each.
- A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney TransplantRecruitingNCT07508787Phase 2
- A Study of SIPLIZUMAB in AILD and LT PatientsRecruitingNCT06455280Phase 1
- Evaluate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.RecruitingNCT06326476Early Phase 1
- Delayed Tolerance Through Mixed ChimerismRecruitingNCT05900401Phase 1/2
- A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal TransplantationTerminatedNCT06365437Phase 2Results posted
- Siplizumab for Sickle Cell Disease TransplantTerminatedNCT06078696Phase 1/2Results posted
- Siplizumab in T1DMTerminatedNCT05574335Phase 1/2Results posted
- A Dose Escalation Study in de Novo Renal TransplantationCompletedNCT04311632Phase 2Results posted
- Renal Allograft Tolerance Through Mixed ChimerismCompletedNCT01780454Phase 1/2Results posted
- Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell LymphomasCompletedNCT01445535Phase 1Results posted
- Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant RejectionCompletedNCT00801632Phase 2Results posted
- A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) PatientsTerminatedNCT06453668Phase 1
- A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes PatientsTerminatedNCT06025110Phase 2
- A Study of TCD601 in the Induction of Tolerance in de Novo Liver TransplantationActive, not recruitingNCT06019507Phase 2
- A Study of TCD601 in de Novo Renal Transplant RecipientsCompletedNCT05669001Phase 2
- A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)TerminatedNCT04803058Phase 2
- A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA)TerminatedNCT04803006Phase 2
- Study of MEDI 507 in the Treatment of Pediatric PatientsCompletedNCT00813618Phase 1
- A Safety Clinical Trial of Different Doses of MEDI-507 in the Prevention of Acute Renal Allograft RejectionCompletedNCT00807794Phase 1
- Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host DiseaseCompletedNCT00806728Phase 1
- Trial for Evaluation of Safety of Escalating Dose Levels of MEDI-507 in Patients for Treatment of at Least Grade II Graft-Versus-Host Disease (GvHD)CompletedNCT00806208Phase 1
- A Phase II Study of MEDI-507, Administered by Injection to Adults With PsoriasisCompletedNCT00540618Phase 2
- Study of MEDI-507 Administered by Intravenous Infusion to Adults With Plaque PsoriasisCompletedNCT00192452Phase 2
- Trial of MEDI-507 in CD2-Positive Lymphoproliferative DiseaseTerminatedNCT00123942Phase 1
- Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic MalignanciesTerminatedNCT00113646Phase 2
- Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/LeukemiaTerminatedNCT00105313Phase 1